ARCHES研究方案:人工智能识别脑出血血肿扩大高风险人群的早期强化降压多中心随机对照试验
ARCHES是一项多中心、前瞻性、随机、开放标签、盲法终点临床试验,计划纳入约680例发病6小时内、基于人工智能血肿扩大5点评分≥3分的高风险脑出血患者,随机接受强化降压(1小时内收缩压130–140 mmHg并维持7天)或标准降压(收缩压140–180 mmHg并维持7天),主要结局为90天死亡或严重残疾。
要点
- 人工智能5点评分(非增强CT深度学习+临床预测因子)用于入院时筛选血肿扩大高风险脑出血患者。
- 强化降压目标为治疗1小时内收缩压130–140 mmHg并维持7天。
- 主要结局为90天死亡或严重残疾。
核心结论
- ARCHES研究旨在验证早期强化降压可减少血肿扩大并改善功能结局且安全性良好的假设。
研究设计与样本
- 多中心、前瞻性、随机、开放标签、盲法终点临床试验,计划纳入约680例参与者。
- 纳入发病6小时内、人工智能血肿扩大5点评分≥3分的脑出血患者。
关键数值与推荐
- 强化降压组:治疗第1小时内收缩压控制在130–140 mmHg,并维持7天。
- 标准降压组:收缩压控制在140–180 mmHg,并维持7天。
- 主要结局:90天死亡或严重残疾。
临床怎么用
- 对发病6小时内脑出血患者,可采用人工智能血肿扩大5点评分筛选高风险人群并启动早期强化降压。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDS: Haematoma expansion (HE) is a significant factor in poor outcomes following intracerebral haemorrhage (ICH). Studies have suggested that acute intensive antihypertensive treatment could reduce HE. However, the impact of early intensive blood pressure reduction on patients with ICH at high risk of HE remains unclear. Therefore, screening ICH patients for high risk of HE upon admission and initiating early intensive blood pressure reduction could improve their prognosis. In this study we utilise a five-point scoring system integrating a deep learning system based on non-contrast CT imaging and clinical predictors to identify ICH patients at high risk of HE. This study aims to compare the efficacy, safety, and feasibility of early intensive antihypertensive treatment versus standard antihypertensive treatment for patients identified as being at high risk of HE. METHODS: The early intensive antihypertensive treatment in high-risk population of intracerebral haemorrhage expansion predicted by artificial intelligence (ARCHES), is a multicentre, prospective, randomised, open-label, blinded-endpoints clinical trial that will include an estimated 680 participants. ICH patients within 6 h of symptom onset, and at high risk of haematoma expansion with ≥ 3 points on the artificial intelligence-based haematoma expansion 5-point prediction score, will be randomly assigned to receive either intensive antihypertensive treatment (targeting systolic blood pressure control between 130 and 140 mmHg within the first hour of treatment, and maintaining this level for 7 days) or standard antihypertensive treatment (targeting systolic blood pressure control between 140 and 180 mmHg, and maintaining for 7 days). The primary outcome is death or severe disability at 90 days. DISCUSSION: The ARCHES study aims to verify the hypothesis that early intensive blood pressure lowering leads to reduced HE and improved functional outcomes with good safety in ICH patients at high risk of HE. TRIAL REGISTRATION: This study was registered at the Clinical Trials under registry number NCT06242938. Registered on Feb 2, 2024. https://clinicaltrials.gov/study/NCT06242938 .
引用
- Wu L, Shan S, Kang K, et al. Early intensive antihypertensive treatment in high-risk population of intracerebral haemorrhage expansion identified by artificial intelligence (ARCHES): study protocol for a multicentre randomised controlled trial. Trials. 2026. PMID: 42286617. doi:10.1186/s13063-026-09833-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。